Wei Guifen, Yuan Yiting, He Xinzhong, Jin Liming, Jin Di
Department of Hepatobiliary and Pancreatic Surgery, The First People's Hospital of Tongxiang, Tongxiang, Zhejiang 314500, P.R. China.
Exp Ther Med. 2019 May;17(5):4190-4196. doi: 10.3892/etm.2019.7438. Epub 2019 Mar 26.
The aim of the present study was to evaluate the expression and specific role of microRNA (miR)-142-5p in the progression of intrahepatic cholangiocarcinoma (ICC). Reverse transcription-quantitative polymerase chain reaction was performed to evaluate miR-142-5p expression in patients with ICC and healthy control subjects. The results revealed that plasma miR-142-5p was significantly increased in patients with ICC compared with the control group. Furthermore, miR-142-5p was also increased in ICC tissues compared with adjacent non-neoplastic tissues. Compared with patients with Ta-T1 stage ICC, miR-142-5p was significantly elevated in patients with ICC ≥T2 stage. Patients with ICC at G3 stage had much higher plasma miR-142-5p levels compared with those at G1/2 stage. Receiver operating characteristic analysis indicated that miR-142-5p could be used as a biomarker to differentiate patients with ICC from healthy controls. Kaplan-Meier analysis demonstrated that plasma miR-142-5p was negatively correlated with survival in patients with ICC. A dual luciferase reporter assay indicated that miR-142-5p significantly suppressed the relative luciferase activity of pmirGLO-PTEN-3' untranslated region compared with the control group. In summary, the results of the present study provide novel data indicating that plasma miR-142-5p is significantly upregulated in patients with ICC. miR-142-5p may therefore have potential as a biomarker for screening patients with ICC from healthy controls.
本研究的目的是评估微小RNA（miR）-142-5p在肝内胆管癌（ICC）进展中的表达及特定作用。采用逆转录定量聚合酶链反应来评估ICC患者和健康对照者中miR-142-5p的表达。结果显示，与对照组相比，ICC患者血浆中的miR-142-5p显著升高。此外，与相邻的非肿瘤组织相比，ICC组织中的miR-142-5p也升高。与Ta-T1期ICC患者相比，ICC≥T2期患者的miR-142-5p显著升高。G3期ICC患者的血浆miR-142-5p水平明显高于G1/2期患者。受试者工作特征分析表明，miR-142-5p可作为区分ICC患者与健康对照者的生物标志物。Kaplan-Meier分析表明，血浆miR-142-5p与ICC患者的生存率呈负相关。双荧光素酶报告基因检测表明，与对照组相比，miR-142-5p显著抑制了pmirGLO-PTEN-3'非翻译区的相对荧光素酶活性。总之，本研究结果提供了新的数据，表明ICC患者血浆中的miR-142-5p显著上调。因此，miR-142-5p可能有潜力作为从健康对照者中筛选ICC患者的生物标志物。
